KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment

Dow Jones

Jan 09

By Kelly Cloonan

Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter.

The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months.

Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July.

"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly," Palleiko said.

The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million.

The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 08, 2026 18:53 ET (23:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602319748"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602319748\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602319748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 07:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602319748","market":"nz","top_or_hot":-1,"title":"KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. \n</p>\n<p>\n  The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months. \n</p>\n<p>\n  Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July. \n</p>\n<p>\n  \"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said. \n</p>\n<p>\n  The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million. \n</p>\n<p>\n  The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 18:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-09 07:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. \n</p>\n<p>\n  The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months. \n</p>\n<p>\n  Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July. \n</p>\n<p>\n  \"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said. \n</p>\n<p>\n  The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million. \n</p>\n<p>\n  The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 18:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALV","symbol_name":"Kalvista Pharmaceuticals Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602319748","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602319748","pubTimestamp":1767916380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter.The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months.Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July.\"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said.The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million.The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"KalVista Pharmaceuticals因遗传疾病治疗的强劲需求而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. \n\n\n  The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months. \n\n\n  Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July. \n\n\n  \"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said. \n\n\n  The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million. \n\n\n  The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 18:53 ET (23:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}